-
-
ETOPOSIDE
- QTY 1
- 50 MG
- Capsule
- Near 43215
ETOPOSIDE, VP-16 (e toe POE side) is a chemotherapy drug. It is used to treat small cell lung cancer and other cancers.
Change Location
Set Price Drop Alert for:
ETOPOSIDE
- QTY 1
- 50 MG
- Capsule
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
ETOPOSIDE
- QTY 1
- 50 MG
- Capsule
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Change Form
Medicine Chest
ETOPOSIDE Lifestyle Interactions
-
Etoposide 50mg, Oral capsule
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: Do not take Etoposide, VP-16 and Grapefruit Juice together without talking to your health care provider. Side effects from Etoposide, VP-16 may get worse if you take Grapefruit Juice. Discuss any new or worsening side effects with your health care provider, including unusual bruising or bleeding, unusual tiredness, fever, signs of infection, or severe nausea / vomiting.• Notes for Professionals: Monitor for an increased incidence of etoposide-related adverse effects if used concomitantly with grapefruit juice. Grapefruit juice is a strong inhibitor of CYP3A4 as well as a P-glycoprotein (P-gp) inhibitor; etoposide, VP-16 is a CYP3A4 and P-gp substrate. Coadministration may cause accumulation of etoposide and decreased metabolism, resulting in increased etoposide concentrations. In a small crossover, randomized trial, 6 patients receiving etoposide for non-small cell lung cancer were treated with 50 mg IV etoposide, 50 mg PO etoposide, or 50 mg PO etoposide following grapefruit juice. Pretreatment with grapefruit juice resulted in a decrease in the AUC of etoposide (average 26.2%) after oral administration; interindividual variability was large in all treatment arms. One suggested mechanism for this interaction is a possible alteration of intestinal p-glycoprotein mediated transport. Due to the small number of patients in this study, no definite conclusions may be drawn.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
